Industrial Policy & Trade Monitor· 2666 actions· ✨ 90 recent

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

President Trump signed a Presidential Proclamation on 20 February 2026 invoking Section 122 of the Trade Act of 1974 (19 U.S.C. § 2132) to impose a temporary 10% ad-valorem import surcharge on articles imported into the United States, effective 12:01 a.m. EST on 24 February 2026. The proclamation was issued within hours of the US Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which held that the International Emergency Economic Powers Act (IEEPA) does not authorize the president to set tariffs and vacated the IEEPA-based reciprocal-tariff regime previously in effect. The Section 122 surcharge is statutorily limited to 150 days (terminates 24 July 2026 absent Congressional extension) and the statute caps any such surcharge at 15% ad valorem. Goods qualifying as USMCA originating from Canada or Mexico are exempt; CAFTA-DR textile/apparel articles meeting specified rules of origin are exempt; and a substantial product-exception list excludes critical minerals, energy products, certain pharmaceuticals, electronics, vehicles, aerospace products, specified agricultural goods, and goods already subject to Section 232 duties (the Section 122 duty does not stack on Section 232).

Brazil's Foreign Trade Chamber Executive Committee (GECEX/CAMEX) adopted Resolução GECEX nº 855 on 13 February 2026, imposing a five-year definitive antidumping duty on hypodermic needles (agulhas hipodérmicas) originating from China, classified under NCM tariff code 9018.32.19 (other tubular metal needles). The duty is collected as a specific tariff fixed in US dollars per thousand units, with rates ranging from USD 0.23 to USD 25.57/thousand units depending on the Chinese producer/exporter. The measure was published in the Diário Oficial da União (DOU Edição 32) on 18 February 2026, enters into force from publication, and marks the first medical-device trade-remedy action on the IPTM register. Scope exclusions cover insulin needles, biopsy needles, animal insemination needles, anesthesia needles, bulk non-sterile needles, and non-hypodermic needles.

On 12 February 2026, Ambassador Jamieson Greer of the Office of the United States Trade Representative oversaw the signing of the US-Taiwan Agreement on Reciprocal Trade (ART) in Washington, DC. The instrument was signed under the auspices of the American Institute in Taiwan (AIT) and the Taipei Economic and Cultural Representative Office in the United States (TECRO). Headline terms: (i) US IEEPA reciprocal-tariff rate on Taiwan reduced from 20% to 15% and Section 232 auto-parts/timber/lumber rate cut from 25% to 15%; (ii) Taiwan eliminates or reduces 99% of its tariff barriers on US goods, most immediately and the remainder phased over three years; (iii) Taiwan side commits ~USD 85bn in directed purchases through 2029 (USD 44.4bn LNG/crude, USD 15.2bn civil aircraft and engines, USD 25.2bn power equipment); (iv) sectoral chapters covering tariffs, non-tariff barriers, digital trade, economic security, and high-tech supply-chain resilience. Operationally linked to the 15 January 2026 AIT-TECRO Memorandum of Understanding on investment, under which Taiwan pledges USD 250bn in direct Taiwanese-enterprise investment in the US plus USD 250bn in Taiwan-government credit guarantees (USD 500bn total) to fund US-side industrial parks/clusters in advanced semiconductors, energy, and AI manufacturing. Entry into force is conditional on Taiwan's Legislative Yuan completing its review.

On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

On 6 February 2026 Presidents Trump and Modi announced a framework for an Interim Trade Agreement that resets the bilateral tariff posture installed in 2025. Two operative instruments: (i) an executive order signed 6 February eliminating, effective 7 February 2026, the additional 25% IEEPA "Russian-oil" duty on Indian imports imposed by EO 14329 (27 August 2025), conditional on India's commitment to cease buying Russian crude and to expand defence cooperation; and (ii) reduction of the EO 14257 reciprocal-tariff rate on India from 25% to 18% on listed product categories (textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home décor, artisanal products, certain machinery), to take effect on finalisation of the Interim Agreement. India commits to eliminate or reduce tariffs on all US industrial goods and a wide range of agricultural products (DDGs, red sorghum, tree nuts, fresh and processed fruit, soybean oil, wine, spirits) and to purchase >USD 500bn of US energy, ICT, coal, aircraft and aircraft parts, and precious-metals products over five years. The framework also commits the parties to negotiating "robust, ambitious, and mutually beneficial digital trade rules" and to addressing non-tariff barriers in medical devices, ICT import licensing, and food/agricultural standards. US tariff reductions on Indian generic pharmaceuticals, gems, diamonds, aircraft parts, and certain automotive components are flagged as contingent on completion of the full Interim Agreement.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 848, de 29 de janeiro de 2026, amending Annexes IV (supply-shortage tariff reductions), V (Letec exceptions list) and VI (LEBIT/BK — IT/telecom and capital-goods exceptions list) of the base tariff-nomenclature resolution (Gecex nº 272/2021). The measure grants a new 0% duty-free tariff-rate quota of 2,500 tonnes/year for poly(oxyethylene) methallyl ether (HPEG, NCM 3907.29.92) through 26 November 2026; adds 0% duty treatment for an esketamine hydrochloride nasal-spray medicine (NCM 3004.90.39) and several pharmaceutical active ingredients including amprenavir and efavirenz (NCM 3004.90.78); and adds cellular base-station antennas (NCM 8517.71.20, 25,000-unit quota through 19 August 2026), diesel-electric locomotives (NCM 8602.10.00, through 25 February 2027) and panoramic maxillary X-ray equipment (NCM 9022.13.11, at a 12.6% rate) to the LEBIT/BK exceptions list. Most changes take effect 1 February 2026 (some 2 February 2026); Article 7 directs SECEX to publish complementary quota-allocation criteria.

India's DGFT issued Notification No. 56/2025-26 on 29 January 2026, amending the import policy under Chapter 29 of ITC (HS) 2022 to impose minimum import prices (MIPs) on three antibiotic Active Pharmaceutical Ingredients (APIs): Penicillin G-potassium (₹2,216/kg CIF), Amoxycillin trihydrate (₹2,733/kg CIF), and 6-Aminopenicillanic Acid/6-APA (₹3,405/kg CIF). Imports below these price floors are reclassified from "Free" to "Restricted" status, requiring a DGFT import authorisation before Customs clearance. The measure takes immediate effect and is valid for approximately ten months (until 30 November 2026), with an implied renewal pathway. It is explicitly aimed at preventing very-low-priced imports and supporting domestic manufacturers built under the PLI Bulk Drugs scheme, targeting China's dominant position in global antibiotic-fermentation supply.

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

India's DGFT issued Notification No. 50/2025-26 on 18 December 2025 (Gazette of India, Extraordinary, Part II, Section 3(ii)), inserting a new Policy Condition No. 08 under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy). Imports of diluted Potassium Clavulanate below a CIF value of USD 77/kg, Potassium Clavulanate (KGA) below USD 180/kg, and specified clavulanic-acid-manufacture intermediates below USD 92/kg are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 November 2026. It is aimed at countering low-priced Chinese potassium-clavulanate exports and protecting Indian bulk-drug fermentation capacity (Aurobindo Pharma and other domestic API makers) amid a global potassium-clavulanate supply glut.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 821, de 1º de dezembro de 2025, amending Annex V (Letec — List of Exceptions to the Common External Tariff) and Annex X (List of Temporary Exceptions for Automotive Products under ACE 14) of the base tariff-nomenclature Resolução Gecex nº 272/2021. The resolution took effect on the date of its publication in the Diário Oficial da União. Global Trade Alert tracks the measure as four discrete tariff-line interventions bundled under one state act: (1) an import-tariff increase on butyl and sodium-polyacrylate chemical inputs, effective 5 December 2025; (2) a reduction of the import tariff to zero for a pharmaceutical product under NCM 3004.90.79, effective 5 December 2025; (3) a new import tariff-rate quota for a chemical/pigment product under NCM heading 3306.11, effective 5 December 2025; and (4) an import-tariff increase on 16 medical-device products under NCM 9018.90.99, effective 2 December 2025. Two of the four sub-measures are duty increases (harmful to importers) and two are duty reductions/new liberalising quotas — consistent with Gecex's routine periodic tariff-schedule maintenance cycle rather than a targeted trade-remedy or industrial-policy action.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

India's DGFT issued Notification No. 41/2025-26 on 10 October 2025, inserting a new import policy condition under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy) for Sulfadiazine API (ITC-HS codes 29359013 and 29359090). Imports with a declared CIF value below Rs. 1,774 per kilogram are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 September 2026, aimed at curbing low-priced imports — Global Trade Alert records China, France and Israel among the affected exporters — while protecting domestic API manufacturers.

The European Commission adopted Implementing Regulation (EU) 2025/1901 on 22 September 2025, imposing definitive anti-dumping duties on imports of glyoxylic acid (CAS 298-12-4, purity ≥95%, CN code ex 2918 30 00, TARIC 2918300013) originating in China for five years. Duty rates are differentiated by exporter: Hubei Hongyuan 29.2%, Xinjiang Guolin 130.0%, other cooperating producers 64.0%, and all non-cooperating Chinese imports 210.5%. The regulation definitively collects provisional duties previously imposed under Regulation (EU) 2025/591 (up to 280.3% provisional rates) from 24 March 2025.

India's DGFT issued Notification No. 30/2025-26 on 18 September 2025, inserting a new import policy condition under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy) for ATS-8 — (4R-Cis)-1,1-Dimethylethyl-6- cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate (HS 2932.99), the key synthesis intermediate for Atorvastatin, a National List of Essential Medicines cholesterol-lowering statin API. Imports with a declared CIF value below USD 111/kg are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 September 2026. Global Trade Alert records China, Argentina and Canada among the affected exporters; global merchant-market ATS-8 supply is concentrated among Chinese producers.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 788, de 10 de setembro de 2025, amending Annex IV of the base tariff-nomenclature resolution (Gecex nº 272/2021) under the Mercosur supply-shortage tariff-reduction mechanism (Mercosur GMC Resolution nº 49/19). The resolution establishes six new duty-free (0%) temporary import tariff-rate quotas: spray-dry detergent powder (800,000 t/year), vitamin B12 (20 t/year), the cell therapy Tisagenlecleucel (48 units), sulphur black dye (6,000 t/year), elastomultiester bicomponent polyester synthetic filament (1,100 t/year), and high-voltage (345kV-class) electrical cable (1,550 t/year). Quotas run for one year from their individual validity start dates, which range from 15 September 2025 to 22 January 2026 depending on product, granting duty-free entry within volume caps where Mercosur-region supply is judged insufficient.

President Trump signed Executive Order 14345 on 4 September 2025, implementing the July 2025 US-Japan trade agreement by setting a 15% baseline ad-valorem tariff on nearly all Japanese goods — raising any Column 1 (MFN) duty rate below 15% up to that floor, including on agricultural lines such as cereals, vegetables, and fruits and nuts. The modification applies retroactively to Japanese products entered for consumption on or after 12:01 a.m. EDT, 7 August 2025, and supersedes the higher 24% country-specific reciprocal rate Japan faced under the April 2025 "Liberation Day" schedule. Aerospace products are exempted entirely, autos/auto parts receive the same 15% treatment (down from a separate 25% Section 232 rate), and Japan committed to $550bn in US investment and $8bn/year in additional US agricultural purchases (rice, corn, soybeans, fertilizer, bioethanol) as consideration.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

On 8 May 2025, President Trump and UK Prime Minister Starmer announced the General Terms of the US-UK Economic Prosperity Deal (EPD), the first bilateral framework arrangement of the second Trump administration and the template instrument for subsequent US bilateral framework deals (US-Japan, US-Indonesia, US-Argentina, US-Korea, US-EU). The framework was implemented on 23 June 2025 via Executive Order 14309 (Federal Register doc 2025-11473). Key US concessions: a 100,000-vehicle annual TRQ for UK autos at a 10% combined rate (7.5% + 2.5% MFN, vs. 27.5% Section 232 default); aerospace tariff reduction back to MFN rates; authority delegated to Commerce/USTR to establish UK-only TRQs for steel and aluminum (in lieu of the 50% Section 232 global rate). Key UK concessions: 13,000 mt duty-free beef quota (with 20% tariff removal on the existing 1,000 mt WTO quota); 1.4 billion litre duty-free ethanol quota; commitment to negotiate non-tariff barrier reductions and supply-chain security alignment. The 10% IEEPA "reciprocal" baseline tariff on most other UK goods is preserved by the EPD.

The Trade Expansion Act of 1962 (Pub. L. 87-794, 76 Stat. 872), signed into law by President Kennedy on 11 October 1962 and codified at 19 U.S.C. §§ 1801–1991, is the foundational US statute granting the executive branch broad authority to negotiate tariff reductions and, critically via Section 232 (19 U.S.C. § 1862), to adjust imports of any article found by the Secretary of Commerce to threaten to impair national security. Section 232 empowers the President — on receipt of a Commerce Department affirmative national-security finding — to impose tariffs, quantitative restrictions, or other import-adjustment measures without congressional approval or WTO-required safeguard procedures. From 1962 to the Trump Administration's 2018–2026 wave of Section 232 Proclamations, the authority was invoked primarily for petroleum and machine-tool imports; since 2018 it has become the legal vehicle for national-security tariffs on steel, aluminum, automobiles, copper, timber, critical minerals, semiconductors, and pharmaceuticals, with 19+ IPTM-filed implementing instruments citing Pub. L. 87-794 / 19 U.S.C. § 1862 as their statutory parent.